企業プロフィール
Bicycle Therapeutics 株価・ニュース・カタリスト
- ティッカー:
- BCYC
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United Kingdom with U
株価パフォーマンス
3.79 USD (-5.49%)
終値
最終更新: 2026年10月6日
300M USD
時価総額
株価変動の要因
2026年10月6日 時点で BCYC は 5.49% 下落し、$3.79 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Bicyclic Peptide Therapeutics Platform
Bicycle Therapeutics develops medicines built from proprietary bicyclic peptides that bind defined disease targets with antibody-like affinity while retaining small-molecule-like size. The platform supports drug conjugates, radioconjugates, imaging agents, and other precision-targeted modalities.
Nuzefatide Pevedotin
Nuzefatide pevedotin is an EphA2-targeting Bicycle Drug Conjugate carrying a cytotoxic payload. The program is being evaluated in recurrent pancreatic ductal adenocarcinoma and has also generated clinical and preclinical evidence across urothelial, head and neck, and other EphA2-expressing cancers.
Zelenectide Pevedotin
Zelenectide pevedotin targets Nectin-4 and is being studied alone and with pembrolizumab in metastatic urothelial cancer. Its design seeks to preserve antitumor activity while reducing toxicities associated with larger antibody-drug conjugates against the same target.
Bicycle Radioconjugates
The company is expanding into radiopharmaceuticals through Bicycle Radioconjugates, which use rapid tumor targeting and clearance characteristics to deliver radioisotopes. Human imaging studies are used to validate target engagement and support selection of therapeutic candidates.
Partnered Platform Economics
Bicycle also collaborates with pharmaceutical companies that apply its technology to targets outside the company's internally prioritized programs. These partnerships can provide research funding, milestones, and royalties while broadening validation of the underlying platform.
今後のカタリスト
- Clinical update from the Phase 2 study of nuzefatide pevedotin in recurrent pancreatic cancer as enrollment and follow-up mature.
- Initiation of the first company-sponsored Phase 1 trial of BT1702, an MT1-MMP-targeting Bicycle Radioconjugate, in 2027.
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。